Fabian Acker

University Hospital Frankfurt

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (11)

Collaborators (4)

Gernot Rohde

Head of department and full professor

University Hospital Frankfurt

Florian Buettner

Goethe University Frankfurt

Julius Enssle

National Institutes of Health

UNITED STATES

Eva Tranter

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Fabian Acker

Research Interests

Explore related searches

Contact this professor

Articles (11)

Collaborators (4)

Gernot Rohde

Florian Buettner

Julius Enssle

Eva Tranter

Make your next move.

Fabian Acker

Research Interests

Explore related searches

Contact this professor

Articles (11)

Real‐world effectiveness of first‐line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy

Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR Inhibition

Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023 with focus on perioperative therapy, radiotherapy and BiTEs.

Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023 with focus on targeted therapies.

Machine-Learning-Aided Prediction Of Brain Metastases Development In Non-Small Cell Lung Cancers

Systemic Treatment for Brain Metastases in NSCLC: A New Chapter

The proteogenomic subtypes of acute myeloid leukemia.

Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis

Study Design and Rationale for the PACE-LUNG Trial: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib First-Line Treatment

KRAS Mutations in Squamous Cell Carcinomas of the Lung

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Collaborators (4)

Gernot Rohde

Florian Buettner

Julius Enssle

Eva Tranter

Make your next move.